News for Rain Therapeutics Inc. (RAIN)

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader...

Sep 08, 2022 / 06:40PM GMTYigal Dov Nochomovitz - Citigroup Inc., Research Division - Director Yigal Nochomovitz, I'm one of the biotech analysts here at Citi.

Sep 10, 2021 / 01:45PM GMTYigal Dov Nochomovitz - Citigroup Inc., Research Division - Director Great. Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the b

4 big analyst cuts: Ambarella takes a plunge

The prevalence of lung adenocarcinoma has been rising over the past few years, which prompts the growing demand for treatment options. The increasing...

4 big analyst cuts: Apple loses buy rating on slack iPhone demand

Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades for Apple, Revolve, Rain Therapeutics, and Intercept Pharmaceuticals. Loop Capital downgraded Apple (NASDAQ:AAPL) to Hold from Buy with a price target of $180.00. The firm sees a material downside risk to revenue (both iPhone and overall) estimates for Q3, relative to both the company’s guidance and Street forecasts.

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.42%

Rain Therapeutics to Resume Trading at 8:30 a.m.

Rain Oncology's stock has fallen near 25% following postponement of milademetan's top-line results and increased net losses reported in Q4 2022 and full year 2022. Click here to read more.

Read Analysts’ New Coverage for June 2nd (ABIO, ACU, AHPI, CALT, CNTB, CRAYF, CREX, EVFM, GALT, GLYC) at ETF Daily News

Read Stock Analysts’ Price Target Changes for May 27th (ACHL, ADEVF, ANPCY, ATDRY, ATGSY, AVDL, BKKVF, BMEA, BNDSF, BNTGY) at ETF Daily News

Gainers